Unravel the Complexities of ADC Manufacturing
Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy but developing and manufacturing them is far from straightforward. Programs must navigate […]
Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy but developing and manufacturing them is far from straightforward. Programs must navigate […]
Sterile injectable (SI) therapies are growing more complex, and regulatory expectations for aseptic fill-finish have never been higher. From revised […]
Highly potent oral solid dosage (HPOSD) products present unique manufacturing and regulatory challenges. As the number of highly potent APIs […]
Developing and manufacturing oral solid dose (OSD) therapies can require specialized expertise, and scalable manufacturing infrastructure. As pipelines span from […]
Drug pipelines are evolving rapidly, with increasing focus on highly potent APIs, targeted therapies, and complex oral solid dose (OSD) […]